« Return to News | Awards & Advancement

Paratek appoints Molnar and Loh to senior positions

Thursday, May 24, 2012 09:00 AM

Paratek Pharmaceuticals of Boston, Mass., has named Dennis Molnar as director, president and CEO, and Evan Loh, MD, as chief medical officer and chairman of the board of directors.  

Molnar, formerly Paratek's vice president of corporate development, has 19 years of experience in the pharmaceutical and biotechnology industries, working in a variety of capacities, including business development, management, finance and consulting. Before joining Paratek in 2001, he served as president of JBI Associates, a software and consulting firm providing services to hospital pharmacies.  Molnar has also served as director of finance and business development at Magainin Pharmaceuticals.  

Loh comes to Paratek from Pfizer where he served as senior vice president of development and strategic operations, worldwide R&D. Prior to joining Pfizer in 2009, Loh was vice president of clinical R&D at Wyeth, where he had global responsibility for scientific, strategic and operational leadership of clinical development efforts across multiple therapeutic areas.  Loh is the 2006 recipient of the Heroes of Chemistry award from the American Chemical Society for his leadership role at Wyeth in the clinical development of Tygacil, a novel glycylcycline broad-spectrum antibiotic. Loh has served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.